ASH 2020: Results of a study investigating zanubrutinib combined with venetoclax for first line treatment of CLL in patients with 17p deletion.
Home / Resource Library / Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial